Advertisement: Simpsons Creative
Advertisement: RSM mid banner
Advertisement: CJBS mid banner
Advertisement: partnersand mid banner
Cambridgeand mid banner advertisement
Barr Ellison Solicitors – commercial property
Advertisement: Kao Data Centre mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: EBCam mid banner
ARM Innovation Hub
Advertisement mid banner S-Tech 1
Advertisement: Cambridge Network mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: Mogrify mid banner
Mid banner advertisement: BDO
Advertisement: HCR Hewitsons mid banner
Advertisement: SATAVIA mid banner
27 January, 2022 - 18:20 By Tony Quested

New chair as Lucida Medical goes for growth

Lucida Medical, a Cambridge-based leader in AI to support magnetic resonance imaging of cancer, has appointed Dr David Tuch – an experienced life science entrepreneur, investor and executive – as non-executive chair. 

He joins to help the company build on tremendous progress during 2021, including a key milestone CE mark for its Pi™ software, and a successful collaboration and technology demonstration with a major vendor and radiology network. 

Dr Tuch will work with the Lucida Medical team to help secure further investment and enable the company to scale and put its technology into the hands of clinicians.

He will work alongside CEO Dr Antony Rix, CTO Mark Hinton, chief medical officer Professor Evis Sala, and existing investors including XTX Ventures.

Dr Tuch received his PhD from MIT and Harvard Medical School working in MRI, inventing and patenting a pioneering method for diffusion-weighted imaging now used worldwide. 

After serving as global head of imaging at Novartis and then head of research alliances at GE Healthcare, Tuch founded Lightpoint Medical to develop a novel miniaturised gamma ray sensor for surgery for prostate cancer and other conditions. He successfully grew Lightpoint Medical as CEO and now serves as executive chair.

Dr Tuch said: “Lucida’s groundbreaking Pi™ cancer imaging and machine learning technology has the potential to address the pressing, global medical need for earlier prostate cancer detection. I am looking forward to working with the executive team and investors to deliver on the promise of Lucida’s remarkable technology.”

Newsletter Subscription

Stay informed of the latest news and features